-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2886 Combination of Olutasidenib and Azacitidine Induces Durable Complete Remissions in mIDH1 Acute Myeloid Leukemia: A Multicohort Open-Label Phase 1/2 Trial

Program: Oral and Poster Abstracts
Session: 617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster II
Hematology Disease Topics & Pathways:
Research, Clinical trials, Adult, Acute Myeloid Malignancies, AML, Combination therapy, Clinical Research, Genetic Disorders, Diseases, Treatment Considerations, Myeloid Malignancies, Study Population, Human
Sunday, December 8, 2024, 6:00 PM-8:00 PM

Jorge E. Cortes, MD1, Gail J. Roboz, MD2, Justin M. Watts, MD3, Maria R. Baer, MD4, Brian A. Jonas, MD, PhD5, Gary J. Schiller, MD6, Karen Yee, MD, FRCPC7*, P. Brent Ferrell, MD8, Jay Yang, MD9, Eunice S. Wang, MD10, William Blum, MD11 and Alice Mims, MD12

1Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA
2Weill Cornell Medicine and The New York Presbyterian Hospital in New York City, New York, NY
3Leukemia Service, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL
4University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
5UC Davis Comprehensive Cancer Center, Davis, CA
6Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA
7Princess Margaret Cancer Centre / University Health Network, Toronto, ON, Canada
8Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN
9Karmanos Cancer Institute, Detroit, MI
10Roswell Park Cancer Institute, Buffalo, NY
11Emory University, Winship Cancer Institute, Atlanta, GA
12The Ohio State University, Columbus, OH

Introduction: Treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML) remains a significant challenge as standard chemotherapies have limited efficacy and may be contraindicated in elderly or frail patients. Relapse and resistance to current therapies are common outcomes, and both quality and length of life decrease with successive lines of therapy. Hypomethylating agents (HMAs), such as azacitidine (AZA), are frequently used for both newly diagnosed and R/R AML, but have limited single-agent responses. Olutasidenib (OLU) is a potent, selective, oral, small molecule inhibitor of mutated IDH1 (mIDH1) and is FDA-approved for treatment of patients with mIDH1 R/R AML. A phase 1/2 registrational trial demonstrated that OLU monotherapy induced complete remission (CR) or CR with partial hematologic recovery (CRh) in 35% of patients with R/R mIDH1 AML for a median duration of 25.9 months. We present a pooled analysis of patients with R/R AML who received a combination of OLU and AZA from the registrational, phase 1/2 trial (clinicaltrials.gov NCT02719574).

Methods: Adult patients with R/R mIDH1R132 AML received twice daily 150 mg OLU (in continuous 28-day cycles) plus standard-of-care AZA (daily for 7 consecutive days, in 28-day cycles) and were evaluated for safety and response.

Results: Sixty-seven patients with R/R mIDH1R132 AML received combination OLU+AZA after a median 10.2 months since AML diagnosis; 43% were refractory and 57% relapsed to prior treatment. Median age was 66 years (range 28-82), and 54% were male. Baseline ECOG was 0-1 in 82%. Most (83%) patients had 2+ prior treatment regimens, including HMA in 40%, IDH1 inhibitor therapy in 31% (olutasidenib monotherapy in 24%), and hematopoietic stem cell transplant (HSCT) in 10%. Cytogenetic risk class was intermediate in 72%, poor in 18% and unknown in 10%. One to 3 co-mutations were identified in 58% of patients, 4-7 in 19%, with FLT3 in 19% and TP53 in 6%.

CR/CRh was achieved in 21/67 (31%; 95% CI, 21-44) patients, and median duration of CR/CRh was 15 months (range 0.4-49). The median time to CR/CRh was 3 months (range 1-10). CR was achieved in 18/67 (27%; 95% CI, 17-39) patients with median duration of 20 months (range 0-44). Overall response (partial remission or better) was achieved in 34/67 (51%; 95% CI, 38-63) patients. In a subset analysis (N=51) excluding patients who had prior OLU exposure, CR/CRh was achieved in 19/51 (37%; 95% CI, 24-52) patients, and CR was achieved in 16/51 (31%; 95% CI, 19-46). Overall response was achieved in 30/51 (59%; 95% CI, 44-72). Duration of CR/CRh was identical for the subset of 51 patients to the full group of 67 patients.

The median overall survival was 13 months (95% CI, 9-19) in 67 patients, 24 months in overall responders, 30.6 months in patients with CR/CRh, and not reached (range 11.5, 55.3+) in patients with CR. Twelve patients (18%) who achieved remission went on to receive HSCT.

Among the full group (N=67), transfusion independence of red blood cells (RBC) and platelets was achieved in 29% and 33% of patients, respectively, who were dependent at baseline. In patients who achieved CR/CRh (n=21), transfusion independence (RBC and platelets) was achieved in 64% (7/11) and 57% (4/7) of patients, respectively, who were dependent at baseline.

The most common Grade 3 or 4 adverse events (≥20% patients) were decreased platelet count (37%), red blood cell count (25%), and neutrophil count (24%). Six patients (9%) experienced differentiation syndrome, of which 2 (3%) were grade 3. Grade 3 or 4 Increases in ALT were reported in 1 patient, AST in 1, ALP in 1, and transaminases in 1. Four patients (6%) discontinued treatment due to an adverse event.

Conclusion: In the first reported analysis of a combination therapy with an mIDH1 inhibitor and an HMA focused on the relapsed/refractory AML setting, olutasidenib plus azacitidine induced high response rates and durable remissions with a tolerable side effect profile in patients with R/R mIDH1 AML.

Disclosures: Cortes: Biopath Holdings: Consultancy, Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees; Nerviano: Consultancy; Ascentage: Research Funding; AbbVie: Research Funding; Syndax: Consultancy; Rigel: Consultancy; Sun Pharma: Consultancy, Research Funding; Pfizer: Consultancy; Novartis: Consultancy, Research Funding; Lilly: Consultancy. Roboz: OncoPrecision: Current holder of stock options in a privately-held company, Honoraria; AbbVie, Amgen, Astrazeneca, Caribou Biosciences, Celgene, Daiichi Sankyo, Ellipses pharma, Geron, GSK, Glycomimetics, Janssen, Jasper Pharmaceuticals, Jazz Pharmaceuticals, Molecular Partners, Oncoverity: Consultancy; Janssen: Research Funding; Novartis, Pfizer, Roche, GlaxoSmithKline, BMS, Syndax, Rigel: Consultancy. Watts: Aptose: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda: Research Funding; Immune Systems Key: Research Funding; Rafael Pharma: Consultancy; Reven Pharma: Consultancy; Daiichi Sankyo: Consultancy; Incyte: Research Funding; Celgene/BMS: Consultancy; Servier: Consultancy, Membership on an entity's Board of Directors or advisory committees; Rigel: Consultancy, Other: safety monitoring or advisory boards, Research Funding. Jonas: AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Daiichi-Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Genentech/Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; GlycoMimetics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Kymera: Consultancy, Membership on an entity's Board of Directors or advisory committees; Servier: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Rigel: Consultancy, Other: Travel; Amgen: Research Funding; AROG: Research Funding; Aptose: Research Funding; Celgene: Research Funding; F. Hoffman-La Roche: Research Funding; Forma Therapeutics: Research Funding; Forty-Seven: Research Funding; Hanmi: Research Funding; Immune-Onc: Research Funding; Incyte: Research Funding; Jazz: Research Funding; Loxo Oncology: Research Funding; Pharmacyclics: Research Funding; Sigma Tau: Research Funding; Treadwell: Research Funding. Yee: Astex: Other: research support; Forma Therapeutics: Other: research support; F. Hoffmann-La Roche: Other: research support; Genentech: Other: research support; Geron: Other: research support; Gilead Sciences: Other: research support; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: research support; Bristol Myers Squibb/Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Membership on an entity's Board of Directors or advisory committees; Jazz: Membership on an entity's Board of Directors or advisory committees; Shattuck Labs: Membership on an entity's Board of Directors or advisory committees; Taiho Pharma: Membership on an entity's Board of Directors or advisory committees; Taiho Pharma: Honoraria. Ferrell: Novartis: Research Funding. Yang: Novartis: Consultancy, Research Funding; Puretech: Research Funding; Pfizer: Research Funding. Wang: Immunogen: Membership on an entity's Board of Directors or advisory committees; UptoDate: Other: Section Editor; Jazz: Consultancy, Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Membership on an entity's Board of Directors or advisory committees; Sumitomo Pharma: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sellas: Membership on an entity's Board of Directors or advisory committees; Stemline: Membership on an entity's Board of Directors or advisory committees; NuProbe: Consultancy, Membership on an entity's Board of Directors or advisory committees; CTI Biopharma: Membership on an entity's Board of Directors or advisory committees; Astellas: Consultancy, Speakers Bureau; Amgen: Membership on an entity's Board of Directors or advisory committees; Dava Oncology: Speakers Bureau; Qiagen: Membership on an entity's Board of Directors or advisory committees; Schrodinger: Membership on an entity's Board of Directors or advisory committees; Rigel: Membership on an entity's Board of Directors or advisory committees; Syndax: Membership on an entity's Board of Directors or advisory committees; PharmaEssentia: Consultancy, Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo: Membership on an entity's Board of Directors or advisory committees; Kite: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Kura: Speakers Bureau; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Mana: Membership on an entity's Board of Directors or advisory committees; J&J: Membership on an entity's Board of Directors or advisory committees; Blueprint: Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Data Safety Monitoring Committee, Award Committee, Research Funding; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Data Safety Monitoring Committee, Research Funding, Speakers Bureau. Mims: BMS: Membership on an entity's Board of Directors or advisory committees; Leukemia and Lymphoma Society Beat AML Study: Other: Senior Medical Director; Daiichi Saynko: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Foghorn Therapeutics: Membership on an entity's Board of Directors or advisory committees; Treadwell Therapeutics: Membership on an entity's Board of Directors or advisory committees.

OffLabel Disclosure: Olutasidenib, approved as a monotherapy

See more of: 617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster II
See more of: Oral and Poster Abstracts
<< Previous Abstract | Next Abstract >>
*signifies non-member of ASH